Phosphospecific antibodies recognising tau
AssigneesAC Immune SA, Katholieke Universiteit Leuven
InventorsAndrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
Claims17
An isolated antibody, or an antigen binding fragment thereof, which recognizes and specifically binds to a phospho-epitope on the mammalian Tau protein or on a fragment thereof, wherein the mammalian Tau protein or fragment thereof comprises a phospho-epitope having, or within, the amino acid sequence VYKSPVVS (Tau aa 393-400 of SEQ ID NO:
- 67) comprising a phosphorylated Ser at position 396 (pS396), wherein said antibody comprises a light chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 106, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 107, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 108;
- and a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 89, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 115, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 91.
An isolated antibody, or an antigen binding fragment thereof, which recognizes and specifically binds to a phospho-epitope on the mammalian Tau protein or on a fragment thereof-, wherein the mammalian Tau protein or fragment thereof comprises a phospho-epitope having, or within, the amino acid sequence VYKSPVVS (Tau aa 393-400 of SEQ ID NO:
- 67) comprising a phosphorylated Ser at position 396 (pS396), wherein said antibody comprises:
- a light chain variable region which is at least 90% identical to SEQ ID NO:
- 105 and has a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 106, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 107, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 108;
- and
- a heavy chain variable region which is at least 90% identical to SEQ ID NO:
- 104 and has a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 89, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 115, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 91.
Dependencies are inferred from the claim text.